Bayer gets USFDA priority review for darolutamide plus docetaxel to treat metastatic hormone-sensitive prostate cancer Ruchika Sharma4 May 2022 6:30 AM GMTDarolutamide is developed jointly by Bayer and Orion Corporation, a globally operating Finnish pharmaceutical company.
Bayer Submits Application for NUBEQA to USFDA and EMA MD Bureau12 March 2022 9:15 AM GMTBayer today announced the submission of a supplemental new drug application to the U.S. Food and Drug Administration USFDA as well as the submission...
Darolutamide increases survival in patients with metastatic, hormone-sensitive prostate cancer: NEJM Medha Baranwal12 March 2022 3:30 AM GMTUSA: Findings from a trial showed that the addition of darolutamide to androgen-deprivation therapy, and docetaxel increased overall survival in...
Darolutamide added to existing combination therapy in metastatic prostate cancer increases survival, NEJM says Medical Dialogues Editorial Team22 Feb 2022 3:30 AM GMTIn a new trial overall survival was remarkably longer with the combination of darolutamide, androgen-deprivation therapy, and docetaxel than with...
Bayer lifts peak sales estimate for prostate cancer drug Nubeqa : Report Ruchika Sharma18 Feb 2022 4:30 AM GMTFrankfurt: A therapy mix including Bayer's Nubeqa drug was shown to significantly prolong the lives of men suffering from metastatic prostate cancer...
Darolutamide improves survival in nonmetastatic prostate cancer patients: NEJM Medha Baranwal12 Sep 2020 4:00 AM GMTDelhi: The administration of Darolutamide in men with nonmetastatic, castration-resistant prostate cancer led to a significantly higher rate...
Darolutamide has considerable added benefit in prostate cancer: Study Hina Zahid4 Aug 2020 6:45 AM GMTUp to now, adult men with non-metastatic castration-resistant prostate cancer (nmCRPC) at high risk of developing metastatic disease usually continued...
